Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification - PubMed (original) (raw)
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
B Mackness et al. FEBS Lett. 1998.
Free article
Abstract
Human serum paraoxonase (PON1) associated with high density lipoprotein (HDL) has been postulated to have a role in protecting low density lipoprotein (LDL) against oxidative modification, which has led to the proposal that PON1 is an anti-atherogenic, anti-inflammatory enzyme. PON1 has two genetically determined polymorphic sites giving rise to amino-acid substitutions at positions 55 (L-->M) and 192 (R-->Q) and therefore 4 potential alloenzymes. We have examined the effects of these molecular polymorphisms on the ability of HDL to protect LDL from oxidative modification. HDL protected LDL from oxidative modification, whatever the combination of PON1 alloenzymes present in it. However, HDL from QQ/MM homozygotes was most effective at protecting LDL while HDL from RR/LL homozygotes was least effective. Thus after 6 h of co-incubation of HDL and LDL with Cu2+ PON1-QQ HDL retained 57 +/- 6.3% of its original ability to protect LDL from oxidative modification, while PON1-QR HDL retained less at 25.1 +/- 4.5% (P < 0.01) and PON1-RR HDL retained only 0.75 +/- 0.40% (P < 0.005). In similar experiments HDL from LL and LM genotypes retained 21.8 +/- 7.5% and 29.5 +/- 6.6% (P = NS), respectively, of their protective ability, whereas PON1-MM HDL maintained 49.5 +/- 5.3% (P < 0.01). PON1 polymorphisms may affect the ability of HDL to impede the development of atherosclerosis and to prevent inflammation.
Similar articles
- Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls.
Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI. Mackness B, et al. Eur J Clin Invest. 2002 Apr;32(4):259-64. doi: 10.1046/j.1365-2362.2002.00977.x. Eur J Clin Invest. 2002. PMID: 11952811 - Lack of protection against oxidative modification of LDL by avian HDL.
Mackness B, Durrington PN, Mackness MI. Mackness B, et al. Biochem Biophys Res Commun. 1998 Jun 18;247(2):443-6. doi: 10.1006/bbrc.1998.8803. Biochem Biophys Res Commun. 1998. PMID: 9642147 - Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs.
Sentí M, Tomás M, Marrugat J, Elosua R; REGICOR Investigators. Sentí M, et al. Arterioscler Thromb Vasc Biol. 2001 Mar;21(3):415-20. doi: 10.1161/01.atv.21.3.415. Arterioscler Thromb Vasc Biol. 2001. PMID: 11231922 - Human serum paraoxonase.
Mackness B, Durrington PN, Mackness MI. Mackness B, et al. Gen Pharmacol. 1998 Sep;31(3):329-36. doi: 10.1016/s0306-3623(98)00028-7. Gen Pharmacol. 1998. PMID: 9703197 Review. - Paraoxonase and coronary heart disease.
Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, Navab M, Shih D, Fonarow GC. Mackness MI, et al. Curr Opin Lipidol. 1998 Aug;9(4):319-24. doi: 10.1097/00041433-199808000-00006. Curr Opin Lipidol. 1998. PMID: 9739487 Review.
Cited by
- Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome.
Olaniyi KS, Areloegbe SE, Badejogbin OC, Ajadi IO, Ajadi MB. Olaniyi KS, et al. Cardiovasc Drugs Ther. 2024 Nov 16. doi: 10.1007/s10557-024-07649-y. Online ahead of print. Cardiovasc Drugs Ther. 2024. PMID: 39549177 - Paraoxonase 1: evolution of the enzyme and of its role in protecting against atherosclerosis.
Durrington P, Soran H. Durrington P, et al. Curr Opin Lipidol. 2024 Aug 1;35(4):171-178. doi: 10.1097/MOL.0000000000000936. Epub 2024 Jun 18. Curr Opin Lipidol. 2024. PMID: 38887979 Free PMC article. Review. - The Association of the Cholesterol Efflux Capacity with the Paraoxonase 1 Q192R Genotype and the Paraoxonase Activity.
Oniki K, Ohura K, Endo M, Akatwijuka D, Matsumoto E, Nakamura T, Ogata Y, Yoshida M, Harada-Shiba M, Saruwatari J, Ogura M, Imai T. Oniki K, et al. J Atheroscler Thromb. 2024 Sep 1;31(9):1263-1276. doi: 10.5551/jat.64711. Epub 2024 Mar 19. J Atheroscler Thromb. 2024. PMID: 38508740 Free PMC article. - CDKN2B-AS (rs2891168), SOD2 (rs4880), and PON1 (rs662) polymorphisms and susceptibility to coronary artery disease and type 2 diabetes mellitus in Iranian patients: A case-control study.
Yari A, Karam ZM, Meybodi SME, Sargazi ML, Saeidi K. Yari A, et al. Health Sci Rep. 2023 Nov 22;6(11):e1717. doi: 10.1002/hsr2.1717. eCollection 2023 Nov. Health Sci Rep. 2023. PMID: 38028681 Free PMC article. - Effect of Exercise Repetitions on Arylesterase Activity of PON1 in Plasma of Average-Trained Men-The Dissociation between Activity and Concentration.
Otocka-Kmiecik A, Orłowska-Majdak M, Stawski R, Szkudlarek U, Padula G, Gałczyński S, Nowak D. Otocka-Kmiecik A, et al. Antioxidants (Basel). 2023 Jun 17;12(6):1296. doi: 10.3390/antiox12061296. Antioxidants (Basel). 2023. PMID: 37372026 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous